People with celiac disease have exactly one option today: a lifelong, strict gluten-free diet. There is no approved drug. Teva has early data suggesting that could change.
In a Phase 2a study, Teva’s experimental antibody TEV-408 — an anti-IL-15 therapy designed for quarterly dosing — produced a “statistically significant and clinically meaningful” reduction in gluten-induced intestinal damage compared with placebo over eight weeks. In celiac disease, the immune system reacts to gluten and attacks the small intestine’s lining; IL-15 is a signaling protein central to that damage.
A broader bet
Teva describes TEV-408 as having “pipeline-in-a-product” potential — meaning the same drug might work across several immune conditions — supported by encouraging Phase 1b results in the skin disorder vitiligo. Further analyses from the ongoing Phase 2a study are underway, with more results expected at a future medical meeting.
Why it matters
Celiac disease affects roughly 1% of people, and even careful eaters get accidental gluten exposure that can cause symptoms and long-term intestinal harm. A drug that blunts the immune damage — letting patients tolerate incidental gluten — would be a genuine first. These are early Phase 2a results, so larger, longer trials are needed before any approval.